Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06629259
PHASE2

Guanfacine for Alcohol Use Disorder (AUD)

Sponsor: Indiana University

View on ClinicalTrials.gov

Summary

The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.

Official title: Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-09-01

Completion Date

2029-09-07

Last Updated

2025-09-18

Healthy Volunteers

No

Interventions

DRUG

Guanfacine Extended Release (XR)

3mg tablet once daily

DRUG

Placebo

placebo tablet once daily

Locations (2)

The Stark Neuroscience Building (Goodman Hall)

Indianapolis, Indiana, United States

Rutgers School of Health Professionals

Newark, New Jersey, United States